COPD with Eosinophils and Exacerbations Carries Higher Burden
Key Takeaways
- In US adults with COPD who had claims evidence of at least 1 day of baseline triple-therapy use and blood eosinophils of at least 150 cells/µL, a recent history of frequent or severe exacerbations was associated with about threefold higher COPD-related exacerbation burden over the next 12 months than in eosinophilic patients without that history.
- The subgroup with blood eosinophils of at least 300 cells/µL showed a follow-up burden pattern that closely resembled the broader exacerbation-prone cohort defined at at least 150 cells/µL.
- COPD-related outpatient, emergency department, and inpatient utilization was higher across the exacerbation-prone eosinophilic cohorts than in the eosinophilic reference group.
- Total COPD-related medical costs were roughly doubled in the exacerbation-prone cohorts, and cardiovascular disorders, depression, gastroesophageal reflux disease, asthma, and allergic rhinitis were more common at baseline.
In a real-world retrospective cohort study using Optum’s de-identified Clinformatics Data Mart Database, which covers more than 28 million US lives with commercial insurance and Medicare Advantage claims, investigators evaluated adults aged 40 years or older who had at least 2 COPD diagnosis claims at least 30 days apart, continuous medical and pharmacy coverage for at least 12 months before and after index, at least 1 day of baseline ICS/LABA/LAMA triple therapy, and an eligible baseline blood eosinophil count measured outside the 14-day systemic corticosteroid window when applicable. The study included 13,840 patients: 6,389 in EXAC-EP-150, 3,100 in the nested EXAC-EP-300 subset, and 7,451 in the reference group. EXAC-EP-150 required at least 2 moderate or at least 1 severe exacerbations in the prior year plus blood eosinophils at least 150 cells/µL; EXAC-EP-300 was the subset with blood eosinophils at least 300 cells/µL; and the reference group had blood eosinophils at least 150 cells/µL without that exacerbation history. Outcomes were COPD-related exacerbations, healthcare resource utilization, and medical costs over 12 months, and analyses were descriptive only with no inferential testing.
During follow-up, mean 12-month rates of any COPD-related exacerbations were 1.58 (1.53, 1.63) in EXAC-EP-150, 1.56 (1.50, 1.63) in EXAC-EP-300, and 0.52 (0.50, 0.54) in the reference group. Moderate exacerbations accounted for most events, and severe exacerbations followed the same pattern at lower frequency. The 2 exacerbation-prone eosinophilic cohorts looked similar to each other and clearly different from the reference group.
Healthcare use and costs followed the same pattern. Mean COPD-related outpatient visit rates were 10.17 (9.81, 10.52), 9.81 (9.31, 10.31), and 5.26 (5.05, 5.48), and emergency department and inpatient visits were also higher in the exacerbation-prone cohorts. Mean total COPD-related medical costs were $12,796 ($11,999, $13,593), $12,287 ($11,136, $13,439), and $5,800 ($5,341, $6,260). Age and sex were similar across groups, while cardiovascular disorders, depression, gastroesophageal reflux disease, asthma, and allergic rhinitis were more common at baseline in the exacerbation-prone cohorts.
These comparisons depended on claims coding for cohort identification, exacerbation classification, utilization estimates, and cost estimates. The authors noted that laboratory values were available for less than half of Optum Clinformatics patients, which could introduce selection bias. They also cautioned that at least 1 day of triple-therapy exposure may not capture stable maintenance treatment, adherence was not assessed, and blood eosinophil counts may still have been influenced by prior corticosteroid use or recent exacerbations despite the timing restriction. The findings describe associations in an insured US population; most patients were reported to have Medicare Advantage coverage (~95%), though the discussion contains conflicting language about generalizability, and the study does not establish causality.
As the authors summarized, exacerbation-prone COPD with type 2 inflammation was associated with higher clinical and economic burden during follow-up than eosinophilic COPD without the same recent exacerbation history. Burden was similar at the 150 and 300 cells/µL blood eosinophil thresholds, reinforcing a consistent pattern in US claims data.
Clinician Questions
Which COPD patients do these claims findings apply to?
These findings apply to insured US adults aged 40 years or older with at least 2 COPD diagnosis claims, at least 1 day of baseline ICS/LABA/LAMA triple therapy, continuous medical and pharmacy coverage for 12 months before and after index, and an eligible baseline blood eosinophil count of at least 150 cells/µL. The comparison was between eosinophilic patients with and without a recent history of frequent or severe exacerbations, and most patients had Medicare Advantage coverage, which limits generalizability.
How were moderate and severe COPD exacerbations defined in this Optum claims analysis?
Moderate exacerbations were outpatient, emergency department, or inpatient visits shorter than 2 days with a COPD diagnosis plus dispensing of systemic corticosteroids and/or a guideline-recommended antibiotic within 14 days, while severe exacerbations were COPD hospitalizations lasting at least 2 days. The investigators used the Mapel healthcare utilization-based algorithm to classify these events.
What limits the comparison between exacerbation-prone eosinophilic COPD and the reference group?
The study was retrospective and descriptive, so it cannot establish causality. Cohort identification and outcome measurement depended on claims coding, laboratory values were available for less than half of Optum Clinformatics patients, triple-therapy exposure of at least 1 day may not reflect stable maintenance use, adherence was not assessed, and eosinophil counts may still have been influenced by prior corticosteroid use or recent exacerbations despite timing restrictions.